Medication Review: Describe the mechanism of action of guselkumab
GHAPPcast5 Des 2024

Medication Review: Describe the mechanism of action of guselkumab

Thank you to Johnson & Johnson for your support of this Medication Review Video Module.

In this medication review, Whitney Steinmetz, NP, from Presbyterian Medical Group in Albuquerque, New Mexico, explores the mechanism of action of Guselkumab, a promising monoclonal antibody therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD).

IBD is driven by chronic gastrointestinal inflammation, resulting from a complex interplay of genetic predisposition, environmental triggers, and immune system dysregulation. A crucial element in this inflammatory process is interleukin-23 (IL-23), a pro-inflammatory cytokine that promotes the differentiation, expansion, and survival of Th17 cells. These Th17 cells produce additional inflammatory cytokines, such as IL-17 and IL-22, which contribute to intestinal inflammation and disease progression.

Guselkumab, a monoclonal antibody therapy, specifically targets the p19 subunit of IL-23, preventing its interaction with the IL-23 receptor on T cells. By blocking IL-23 signaling, Guselkumab reduces Th17 cell activation and cytokine production, leading to a decrease in gut inflammation. This mechanism positions Guselkumab as a promising treatment option for IBD, aiming to mitigate chronic inflammation, improve mucosal healing, and enhance patient outcomes.

For more information on IL-23 inhibitors, biologic therapies, and advancements in gastroenterology, visit GHAPP.org or download the GHAPP ACE app on IOS and Android. Follow us on LinkedIn, YouTube, X (Twitter), and Instagram for the latest updates and expert insights.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(162)

Podcast: How to Screen and Diagnose Cholestatic Liver Diseases

Podcast: How to Screen and Diagnose Cholestatic Liver Diseases

In this episode, HoChong Gilles of the Richmond VA Medical Center, and Alison Moe of Atlanta Gastroenterology discuss a practical, step-by-step approach to screening for and diagnosing cholestatic liv...

25 Aug 20min

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Aug 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Aug 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Aug 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Jul 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Jun 17min

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC,...

9 Jun 12min

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Jun 4min

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
psykodrama
hvordan-har-du-det-mann
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-skravla-gar
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
morten-ramm-lar-kakla-ga-til-du-sovner
foreldreradet
hjernesterk
rss-lopedrommen
g-punktet
rss-garne-damer
kjed-deg-i-sovn-verdens-kjedeligste-podcast
klimaks
treningsprat
hormonelle-frida
sinnsyn